| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Coherus Oncology, Inc. (CHRS) has 3 insiders with recent SEC Form 4 filings, including 0 buys and 12 sells. CHRS is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| Dir | 30.0K | $44.4K | - | |
| CFO | 15.0K | $22.2K | - | |
| CEO | 0 | - | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Jul 10, 2018 | Finck Barbara K | Chief Medical Officer | Sale+OE | 1,760 | $15.01 | $26,415.00 | -2.3% | |
| Jun 18, 2018 | Finck Barbara K | Chief Medical Officer | Sale+OE | 1,760 | $15.00 | $26,400.00 | -4.5% | |
| May 16, 2018 | Lanfear Dennis M | See Remarks | Sell | 20,984 | $16.26 | $341,264.89 | -1.6% | |
| Aug 8, 2017 | Herman Alan C. | Chief Scientific Officer | Sell | 17,535 | $15.02 | $263,300.30 | -26.1% | |
| Jul 5, 2017 | Herman Alan C. | Chief Scientific Officer | Sell | 600 | $15.00 | $9,000.00 | -0.9% | |
| Jun 1, 2017 | Herman Alan C. | Chief Scientific Officer | Sell | 11,333 | $20.32 | $230,291.84 | -7.6% | |
| May 1, 2017 | Herman Alan C. | Chief Scientific Officer | Sell | 11,333 | $20.00 | $226,626.00 | -12.5% | |
| Apr 3, 2017 | Herman Alan C. | Chief Scientific Officer | Sell | 11,333 | $20.73 | $234,985.22 | -11.1% | |
| Mar 1, 2017 | Herman Alan C. | Chief Scientific Officer | Sell | 11,333 | $24.19 | $274,171.34 | -10.0% | |
| Feb 1, 2017 | Herman Alan C. | Chief Scientific Officer | Sell | 11,333 | $27.37 | $310,154.74 | -9.1% |